As extra Individuals flip to weight reduction medicine, the U.S. grownup weight problems fee is declining, in line with new survey information from Gallup.
The info revealed Tuesday confirmed the weight problems fee amongst individuals has progressively declined to 37% in 2025 after beforehand hitting a document excessive of 39.9% in 2022. Outcomes have been primarily based on information from three nationally consultant surveys of 16,946 U.S. adults interviewed by internet within the first three quarters of 2025.
“This can be a statistically significant lower representing an estimated 7.6 million fewer overweight adults in contrast with three years in the past,” the report famous.
Within the report, weight problems was outlined utilizing the federal normal of getting a BMI of 30 or increased.
The report additionally explored the simultaneous improve in GLP-1 drug utilization for weight reduction, together with semaglutides like Ozempic and Wegovy. These medicine are additionally used to deal with kind 2 diabetes, which the report famous was nonetheless at an all-time excessive, with 13.8% of Gallup’s Effectively-Being Index individuals saying they have been identified with the continual illness.
When Gallup first measured GLP-1 utilization in February 2024, 5.8% of adults reported taking any such medication for weight reduction. Now, the share has elevated to 12.4%, the report stated.
“Amid elevated use of GLP-1 injectables for weight reduction, weight problems charges have been coming down for many age teams since 2022,” the report added.
The report discovered the most important discount in weight problems was amongst these aged 40 to 49 and people aged 50 to 64. These are the identical age teams with the very best charges of GLP-1 injectables for weight reduction, the report stated.
The report does have some limitations, nevertheless, together with potential bias in how respondents current themselves.
“Nonetheless, as a result of Gallup’s methodology of gathering self-reported weight and top has been constant, the development nonetheless offers helpful data concerning adjustments over time,” the report stated.
Gallup additionally didn’t measure GLP-1 utilization for weight reduction in 2022 or 2023, however stated out there information through its Effectively-Being Index are “in keeping with stories of steadily rising use for the reason that preliminary FDA approval in 2021.”
Regardless of the reported decline in weight problems charges, the U.S. continues to exceed many Western international locations in weight, the report identified — however increasing entry to weight reduction therapies could also be an element within the weight problems decline turning into an enduring development, the authors word.
Round 40% of adults within the U.S. are overweight, information from the Facilities for Illness Management and Prevention recommended in September 2024 — marking the primary time in over a decade that the nation’s weight problems fee has not inched up, outcomes from the federal authorities’s nationwide well being survey confirmed.
